New combo therapy aims to zap tumors with less radiation
NCT ID NCT04381806
Summary
This early-stage study is testing whether a lower, potentially safer dose of radiation can effectively treat advanced solid tumors when combined with a drug called 5-aminolevulinic acid (ALA). The drug is meant to make cancer cells more sensitive to the radiation, which could help target tumors while reducing damage to nearby healthy tissue. The trial aims to find the safest and most effective dose of this combination for patients whose cancer has not responded to standard treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
Conditions
Explore the condition pages connected to this study.